TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05603715: Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Sponsor: University of Vermont Medical Center · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT05603715 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05603715 Rescue Dossier →